文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

术中配准超声与透视(iRUF)用于前列腺近距离治疗剂量计算的准确性优于标准超声剂量学

Intraoperative Registered Ultrasound and Fluoroscopy (iRUF) for dose calculation during prostate brachytherapy: Improved accuracy compared to standard ultrasound-based dosimetry.
PubMed 文献 · Radiother Oncol · 2017-06-21

结果显示,与术后第1天CT/MRI剂量学相比,iRUF的整体ICC为0.42(USD为0.01),整体均方根差异为16.5(USD为21.5),表明iRUF更接近术后CT/MRI的剂量学结果。

要点

  • iRUF与术后CT/MRI剂量学的整体ICC为0.42,而USD仅为0.01。
  • iRUF的整体均方根差异为16.5,显著小于USD的21.5。
  • USD与iRUF相比倾向于高估前列腺剂量。

核心结论

  • iRUF在近似术后CT/MRI前列腺和尿道剂量学方面优于标准超声剂量学(USD)。

研究设计与样本

  • 术中完成植入后使用移动C臂采集6张X射线图像和经直肠超声横向图像,重建种子三维位置并配准进行iRUF剂量学计算。
  • 术后第1天进行CT/MRI扫描用于术后剂量学评估,分别计算iRUF、USD和CT/MRI数据集的前列腺和尿道剂量学参数。

主要发现

  • 与CT/MRI相比,iRUF剂量学的整体ICC为0.42,而USD为0.01。
  • iRUF的整体均方根差异为16.5,USD为21.5。
  • USD与iRUF相比倾向于高估前列腺剂量。

关键数值与推荐

  • iRUF与CT/MRI的整体ICC为0.42(USD为0.01)。
  • iRUF与CT/MRI的整体均方根差异为16.5(USD为21.5)。

临床怎么用

  • iRUF可术中提供更接近术后CT/MRI的前列腺和尿道剂量学评估,优于标准超声剂量学。
  • 正在开展一项使用iRUF进行术中动态计划修改的II期试验,旨在确认其最小化和纠正未检测到的前列腺剂量不足的能力。

局限性

  • 本文为初步研究(pilot study),最终仅分析66例符合条件患者的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Intraoperative transrectal ultrasound dosimetry during low-dose-rate prostate brachytherapy is imprecise due to sonographic distortion caused by seed echoes and needle tracks that obscure seed positions or create false signals as well as traumatic edema. Here we report the results of a pilot study comparing a combined ultrasound and fluoroscopy-based seed localization method (iRUF) to standard ultrasound-based dosimetry (USD). MATERIAL AND METHODS: Eighty patients undergoing permanent Pd-103 seed implantation for prostate cancer were prospectively enrolled. Seed implantation was performed using standard USD for intraoperative dose tracking. Upon implant completion, six X-ray images were intraoperatively acquired using a mobile C-arm and transverse ultrasound images of the implanted prostate were also acquired. Three-dimensional seed locations were reconstructed from X-ray images and registered to the ultrasound for iRUF dosimetry. Day 1 CT/MRI scans were performed for post-implant dosimetry. Prostate and urethral dosimetric parameters were separately calculated for analysis on iRUF, USD, and CT/MRI data sets. Differences and similarities between dosimetric values measured by iRUF, USD, and CT/MRI were assessed based on root mean squared differences, intraclass correlation coefficients (ICC), and Wilcoxon signed rank test. RESULTS: Data from 66 eligible patients were analyzed. Compared to CT/MRI, iRUF dosimetry showed higher correlation with overall ICC of 0.42 (0.01 for USD) and significantly smaller root mean squared differences (overall 16.5 vs 21.5 for iRUF and USD) than USD for all prostate and urethral dosimetric parameters examined. USD demonstrated a tendency to overestimate dose to the prostate when compared to iRUF. CONCLUSIONS: iRUF approximated post-implant CT/MRI prostate and urethral dosimetry to a greater degree than USD. A phase II trial utilizing iRUF for intraoperative dynamic plan modification is underway, with the goal to confirm capability to minimize and correct for prostate underdosage not otherwise detected.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Lee J, Mian OY, Le Y, et al. Intraoperative Registered Ultrasound and Fluoroscopy (iRUF) for dose calculation during prostate brachytherapy: Improved accuracy compared to standard ultrasound-based dosimetry. Radiother Oncol. 2017. PMID: 28647400. doi:10.1016/j.radonc.2017.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。